Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immun...

Full description

Bibliographic Details
Main Authors: Yan Yang, Zheng Yang, Yun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
bispecific antibodies (bsAbs)
CD47
immune checkpoint
macrophage
phagocytosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.686031/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.686031/full

Similar Items